Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2007-12-14 Capital/Financing Update
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2007
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock option plans. It includes detailed information about the securities to be registered, the plans under which they are offered, indemnification of officers, and references to other SEC filings like Form 20-F and Form 6-K. This is a capital markets filing related to share registration for employee stock options, not a financial report, earnings release, or management discussion. The Form S-8 is a registration statement for securities offerings under employee plans, which falls under capital/financing updates rather than annual reports or other categories. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a certification but a full registration statement.
2007-12-14 English
Regulatory Filings 2007
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, XTL Biopharmaceuticals Ltd. It reports on scientific presentations related to the company's pre-clinical Hepatitis C virus program at a conference. The content is an announcement of data presentations and forward-looking statements, not a full financial report or detailed management discussion. The document length is 7275 characters, which is relatively short and primarily serves as a regulatory announcement of new scientific data and company updates. It does not contain financial statements, earnings data, or detailed management analysis. Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2007-12-10 English
Other Report or Announcement
Regulatory Filings Classification · 95% confidence The document is a press release announcing scientific presentations related to the company's pre-clinical Hepatitis C virus small molecule program at a scientific conference. It contains no financial data, no regulatory filing references, no voting results, no management or board changes, no earnings or interim report data, and no capital or financing updates. It is primarily a corporate announcement about research and development progress and upcoming presentations at a conference. The document length is 5714 characters, which is relatively short and consistent with a press release rather than a full report. There is no indication that this is an Annual Report, Interim Report, Earnings Release, or any other formal regulatory filing. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other categories.
2007-12-10 Hebrew (modern)
Other Report or Announcement
Report Publication Announcement Classification · 98% confidence The document is very short (1637 characters) and explicitly states that an attachment is being provided: "Attached hereto is a report on *Presentation at an International Scientific Conference on Hepatitis*". This structure—a brief filing announcing the availability of a separate, specific report—fits the definition of a Report Publication Announcement (RPA). The content of the attachment is a presentation, which aligns with the general nature of investor/scientific updates, but the filing itself is the announcement of that publication, not the presentation content itself. Since RPA is available, it takes precedence over the general fallback (RNS).
2007-12-10 English
Major Shareholding Notification 2007
Major Shareholding Notification
2007-12-07 English
FORM 3
Director's Dealing
2007-12-07 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.